Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : VD's Model Portfolio & Discussion Thread -- Ignore unavailable to you. Want to Upgrade?

To: Rocketman who wrote (5787)	10/22/1998 10:03:00 PM
From: Andrew H	Read Replies (1) \| Respond to of 9719

AMLN looks pretty cheap here, altho they are most likely dead longer term. However just the fact that US trials are continuing ought to make them worth more than .5/share. On another note, I just noticed how cheap GZTC has gotten. Long term prospects are incredible. 4 new major collaborations this Q alone. However, it is strange that there has been no word on the P2 AT111 trials when P3s have been going on for quite a while. Surely they must have had to show the results to the FDA to get approval for P3. GZTC has an awful lot of major collaborations going on--if even 1/4 of these are successful, the stock will be huge. Selling for $4. From today's quarterly: >>Lehrman described accomplishments for the quarter as follows: -- Entered option and licensing agreement with Eli Lilly and Co. to develop a novel therapeutic protein to be produced transgenically. Under the terms, Genzyme Transgenics will receive development funding through the option period, and upon Lilly 's exercise of the option, will receive development funding and milestone payments up to $22 million. Genzyme Transgenics will manufacture the protein for Lilly and receive royalties on the sales, while Lilly will receive global commercialization rights. -- Entered into a Collaborative Research and Development Agreement (CRADA) with the National Institute of Allergy and Infectious Diseases, National Institutes of Health (NIAID, NIH) to produce and evaluate the first transgenically-produced candidate malaria vaccine. The company previously announced that it had achieved high-level expression of the candidate vaccine antigen, termed MSP-1, in the milk of transgenic mice, and signed a letter of intent to enter into the CRADA with NIAID in January, 1998. These collaborative studies will be the first to test the feasibility of using a protein from a transgenic animal as a potential vaccine for a major infectious disease. -- Initiated a collaboration with BioSyn Holding AB (Stockholm, Sweden) to evaluate and develop an orally-administered diabetes vaccine containing recombinant human glutamic acid decarboxylase, (rhGAD). Genzyme Transgenics previously announced the high level expression of the GAD protein in the milk of transgenic mice and under this collaboration with BioSyn, will develop transgenic rabbits. GAD has been extremely difficult to produce for potential commercialization because the protein is not normally secreted by cells. Genzyme Transgenics has developed proprietary transgenic expression technology that allows GAD to be secreted into the milk of transgenic animals. -- Announced agreement with Interferon Sciences, Inc. to develop transgenically produced versions of human interferon alpha (IFN-a). Under the terms of their agreement, the two companies will form a joint venture, which will own the rights for the commercialization and therapeutic use of transgenically produced IFN-a. Each party will equally contribute to costs related to the development of the transgenically produced IFN-a products and will equally share any milestone payments or other success fees received. On October 19, 1998, Genzyme Transgenics began the new quarter by announcing that it had initiated its twelfth development program for an antibody-based therapeutic. This collaboration with an unnamed West Coast pharmaceutical company is potentially worth $35 million in annual revenues to Genzyme Transgenics. <<